Figure 1 | Scientific Reports

Figure 1

From: TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System

Figure 1

Number of patients initiating TNF-alpha inhibitor (a) and prevalent users of TNF-alpha inhibitor (b) between year − 1 and 6 (if applicable) after first biosimilar entry for each molecule. ADA, ETA and INF refer to adalimumab, etanercept and infliximab respectively. Adalimumab year 2 was 98% complete, infliximab year 6 67% and etanercept year 5 39%, from market entry date anniversary to study end date.

Back to article page